Published in PLoS One on August 12, 2013
Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr (2016) 0.86
Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India. Medicine (Baltimore) (2016) 0.85
HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia. J Int AIDS Soc (2014) 0.82
Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis (2014) 0.81
Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings. Medicine (Baltimore) (2016) 0.80
Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. PLoS One (2015) 0.78
Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women. PLoS One (2015) 0.78
Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo. AIDS Res Ther (2015) 0.77
Combination Antiretroviral Therapy for HIV in Rwandan Adults: Clinical Outcomes and Impact on Reproductive Health up to 24 Months. AIDS Res Treat (2015) 0.75
Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections. Ann Clin Microbiol Antimicrob (2016) 0.75
HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother (2016) 0.75
HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China. PLoS One (2017) 0.75
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet (2006) 11.06
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis (2011) 5.94
An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (2005) 5.60
Public health implications of antiretroviral therapy and HIV drug resistance. JAMA (1998) 4.72
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis (2010) 4.41
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (2008) 4.00
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS (2005) 3.71
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther (2008) 3.53
Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health (2012) 3.43
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med (2009) 3.42
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med (2000) 3.25
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One (2011) 2.84
Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr (2011) 2.80
Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making (2001) 2.45
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis (2012) 2.26
Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis (2011) 2.15
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther (2012) 1.71
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis (1997) 1.23
The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis (2012) 1.21
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother (2009) 1.17
Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. Clin Infect Dis (2012) 1.11
(ARV-) Free State? The moratorium's threat to patients' adherence and the development of drug-resistant HIV. S Afr Med J (2009) 1.09
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol (2004) 1.09
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS (2002) 1.05
Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc (2012) 1.05
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr (2010) 1.01
Patient enrolment into HIV care and treatment within 90 days of HIV diagnosis in eight Rwandan health facilities: a review of facility-based registers. PLoS One (2012) 0.94
Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care (2013) 0.92
Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda. PLoS One (2012) 0.85
New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet (2008) 11.20
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis (2008) 3.98
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis (2011) 2.70
Microfluidics-based diagnostics of infectious diseases in the developing world. Nat Med (2011) 2.68
Promotion of couples' voluntary counselling and testing for HIV through influential networks in two African capital cities. BMC Public Health (2007) 2.55
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
Access to adequate nutrition is a major potential obstacle to antiretroviral adherence among HIV-infected individuals in Rwanda. AIDS (2006) 2.23
Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda. Clin Infect Dis (2013) 2.22
Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS (2010) 2.17
Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses (2010) 2.05
A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses (2007) 1.92
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis (2002) 1.87
Role of traditional birth attendants in preventing perinatal transmission of HIV. BMJ (2002) 1.72
Mobile device for disease diagnosis and data tracking in resource-limited settings. Clin Chem (2013) 1.72
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One (2010) 1.71
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56
Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt) (2005) 1.56
Indeterminate and discrepant rapid HIV test results in couples' HIV testing and counselling centres in Africa. J Int AIDS Soc (2011) 1.55
Avian influenza--a challenge to global health care structures. N Engl J Med (2004) 1.55
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study. J Int AIDS Soc (2010) 1.54
Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native Africans. J Virol (2006) 1.52
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
HIV infection and sexual behaviour in primary and secondary infertile relationships: a case--control study in Kigali, Rwanda. Sex Transm Infect (2010) 1.51
High incidence of asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex Transm Dis (2009) 1.49
Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya. PLoS One (2011) 1.47
Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods (2009) 1.46
Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis (2010) 1.43
Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS (2012) 1.41
Absolute CD4 T-cell counting in resource-poor settings: direct volumetric measurements versus bead-based clinical flow cytometry instruments. J Acquir Immune Defic Syndr (2005) 1.40
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Knowledge, use, and concerns about contraceptive methods among sero-discordant couples in Rwanda and Zambia. J Womens Health (Larchmt) (2009) 1.35
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci U S A (2011) 1.30
Determinants of prevalent HIV infection and late HIV diagnosis among young women with two or more sexual partners in Beira, Mozambique. PLoS One (2013) 1.27
Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics (2006) 1.25
Influence network effectiveness in promoting couples' HIV voluntary counseling and testing in Kigali, Rwanda. AIDS (2012) 1.25
HIV incidence remains high in KwaZulu-Natal, South Africa: evidence from three districts. PLoS One (2012) 1.23
Voluntary counseling and testing for HIV among pregnant women presenting in labor in Kigali, Rwanda. J Acquir Immune Defic Syndr (2002) 1.21
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Knowledge and perceptions of couples' voluntary counseling and testing in urban Rwanda and Zambia: a cross-sectional household survey. PLoS One (2011) 1.18
High seroprevalence of HBV and HCV infection in HIV-infected adults in Kigali, Rwanda. PLoS One (2013) 1.16
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. PLoS One (2008) 1.15
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS (2002) 1.13
Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS Res Ther (2007) 1.13
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLoS One (2012) 1.13
Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13
HIV incidence and HIV testing behavior in men who have sex with men: using three incidence sources, The Netherlands, 1984-2005. AIDS (2007) 1.13
Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa. AIDS (2013) 1.13
Performance of VIDISCA-454 in feces-suspensions and serum. Viruses (2012) 1.10
The spectrum of central nervous system infections in an adult referral hospital in Hanoi, Vietnam. PLoS One (2012) 1.09
Triple HIV-1 infection. N Engl J Med (2005) 1.09
Predictors of HIV serostatus among HIV discordant couples in Lusaka, Zambia and female antenatal clinic attendants in Kigali, Rwanda. AIDS Res Hum Retroviruses (2005) 1.09
Preparation of nanostructures by orthogonal self-assembly of hydrogelators and surfactants. Angew Chem Int Ed Engl (2008) 1.09
Pregnancy, hormonal contraceptive use, and HIV-related death in Rwanda. J Womens Health (Larchmt) (2007) 1.07
HIV-1 dual infection is associated with faster CD4+ T-cell decline in a cohort of men with primary HIV infection. Clin Infect Dis (2011) 1.07
Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: a qualitative study. PLoS One (2013) 1.06
Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions. AIDS (2005) 1.06
Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J Virol Methods (2003) 1.06
HIV infection, malaria, and pregnancy: a prospective cohort study in Kigali, Rwanda. Am J Trop Med Hyg (2002) 1.05
Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog (2013) 1.05
Microbicides to prevent heterosexual transmission of HIV: ten years down the road. BETA (2002) 1.05
WHO's new guidelines for antiretroviral treatment. Lancet (2013) 1.04
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother (2002) 1.04
Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries. Sex Transm Infect (2011) 1.03
HIV RNA levels in transmission sources only weakly predict plasma viral load in recipients. AIDS (2010) 1.01
Is vaginal washing associated with increased risk of HIV-1 acquisition? AIDS (2006) 1.01
Developing standards of care for HIV prevention research in developing countries -- a case study of 10 research centers in Eastern and Southern Africa. AIDS Care (2012) 1.01
Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One (2012) 1.00
Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS (2004) 1.00
HIV-infected Rwandan women have a high frequency of long-term survival. AIDS (2007) 0.99
Improved access increases postpartum uptake of contraceptive implants among HIV-positive women in Rwanda. Eur J Contracept Reprod Health Care (2009) 0.99
Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther (2006) 0.99
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics (2006) 0.99
The relationship between alcohol consumption and unprotected sex among known HIV-discordant couples in Rwanda and Zambia. AIDS Behav (2007) 0.96
Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM? PLoS One (2013) 0.95
Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J Virol (2011) 0.94
Fertility goal-based counseling increases contraceptive implant and IUD use in HIV-discordant couples in Rwanda and Zambia. Contraception (2012) 0.94
The co-selection of fluoroquinolone resistance genes in the gut flora of Vietnamese children. PLoS One (2012) 0.94
Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection. J Leukoc Biol (2011) 0.94
Antiretroviral therapy drug adherence in Rwanda: perspectives from patients and healthcare workers using a mixed-methods approach. AIDS Care (2013) 0.92
Vaginal practices among women at high risk of HIV infection in Uganda and Tanzania: recorded behaviour from a daily pictorial diary. PLoS One (2013) 0.92
Incidence of human immunodeficiency virus type 1 dual infections in Amsterdam, The Netherlands, during 2003-2007. Clin Infect Dis (2009) 0.91
HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS (2004) 0.91
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics (2007) 0.90